Exelixis
EXEL
#1725
Rank
C$13.65 B
Marketcap
$47.83
Share price
-1.16%
Change (1 day)
53.35%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Exelixis (EXEL) - Cash on Hand

Cash on Hand as of September 2024 : C$1.70 Billion

According to Exelixis's latest financial reports the company has C$1.70 Billion in cash and cash equivalents.
A companyโ€™s cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.

Exelixis - Cash on Hand chart (from 2000 to 2024)

Cash on Hand by year

Year Cash on Hand Change
2023-12-31C$1.32 B-25.65%
2022-12-31C$1.77 B-5.04%
2021-12-31C$1.86 B21.53%
2020-12-31C$1.53 B38.21%
2019-12-31C$1.11 B17.85%
2018-12-31C$0.94 B93.73%
2017-12-31C$0.48 B-13.58%
2016-12-31C$0.56 B143.44%
2015-12-31C$0.23 B38.41%
2014-12-31C$0.16 B-35.12%
2013-12-31C$0.25 B-36.92%
2012-12-31C$0.40 B107.05%
2011-12-31C$0.19 B21.53%
2010-12-31C$0.16 B-23.91%
2009-12-31C$0.21 B-33.02%
2008-12-31C$0.31 B17.78%
2007-12-31C$0.27 B30.06%
2006-12-31C$0.20 B20.36%
2005-12-31C$0.17 B-7.16%
2004-12-31C$0.18 B-39.4%
2003-12-31C$0.30 B-12.28%
2002-12-31C$0.35 B-3.34%
2001-12-31C$0.36 B115.11%
2000-12-31C$0.16 B1594.42%
1999-12-31C$9.95 M

Cash on Hand for similar companies or competitors

Company Cash on Hand differencediff. Country
C$6.17 B 261.49%๐Ÿ‡ฌ๐Ÿ‡ง UK
C$10.46 B 512.54%๐Ÿ‡ซ๐Ÿ‡ท France
C$20.96 B 1,127.17%๐Ÿ‡บ๐Ÿ‡ธ USA
C$11.62 B 580.65%๐Ÿ‡บ๐Ÿ‡ธ USA
C$12.94 B 657.76%๐Ÿ‡บ๐Ÿ‡ธ USA
C$29.16 B 1,606.84%๐Ÿ‡บ๐Ÿ‡ธ USA
C$14.29 B 736.89%๐Ÿ‡บ๐Ÿ‡ธ USA
C$29.96 M-98.25%๐Ÿ‡บ๐Ÿ‡ธ USA
C$0.11 B-93.49%๐Ÿ‡บ๐Ÿ‡ธ USA